Edition:
United States

Boston Scientific Corp (BSX.N)

BSX.N on New York Stock Exchange

26.77USD
21 Feb 2018
Change (% chg)

$-0.06 (-0.22%)
Prev Close
$26.83
Open
$26.87
Day's High
$27.27
Day's Low
$26.74
Volume
1,592,934
Avg. Vol
2,115,087
52-wk High
$29.92
52-wk Low
$23.30

Select another date:

Tue, Feb 20 2018

BRIEF-Boston Scientific Corp Files For Potential Debt Shelf Offering

* BOSTON SCIENTIFIC CORP FILES FOR POTENTIAL DEBT SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING‍​ Source text: (http://bit.ly/2GtreIT) Further company coverage:

4th Circuit upholds $18.5 mln mesh verdict against Boston Scientific

A federal appeals court on Tuesday upheld a 2014 verdict ordering Boston Scientific Corp to pay four women a total of $18.5 million for injuries caused by the company's transvaginal mesh devices.

Boston Scientific forecast disappoints, eyes M&As

Boston Scientific Corp forecast full-year earnings largely below Wall Street estimate and the medical device maker said it would likely do three or four acquisitions in the next 18 months.

UPDATE 2-Boston Scientific forecast disappoints, eyes M&As

* Shares fall 1.7 pct (Adds conference call details, analysts comments, updates shares)

CORRECTED-UPDATE 1-Boston Scientific's sales beat, forecasts 2018 revenue above estimates

Feb 1 Boston Scientific Corp on Thursday forecast better-than-expected 2018 revenue after the medical device maker's fourth-quarter sales beat Wall Street estimates on higher sales in its cardiac rhythm management unit.

Boston Scientific posts quarterly loss due to tax charge

Feb 1 Medical device maker Boston Scientific Corp posted a quarterly loss versus a year-ago profit as it incurred a $842 million charge due to changes in the U.S. tax law.

BRIEF-Boston Scientific Reports Q4 Adjusted Earnings Per Share $0.34

* BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FOURTH QUARTER AND FULL YEAR 2017

BRIEF-Boston Scientific Announces Investment And Acquisition Option Agreement With Millipede, Inc.

* BOSTON SCIENTIFIC ANNOUNCES INVESTMENT AND ACQUISITION OPTION AGREEMENT WITH MILLIPEDE, INC.

BRIEF-Boston Scientific Receives U.S. FDA Approval For Spectra Wavewriter Spinal Cord Stimulator System

* BOSTON SCIENTIFIC RECEIVES U.S. FDA APPROVAL FOR SPECTRA WAVEWRITER™ SPINAL CORD STIMULATOR SYSTEM Source text for Eikon: Further company coverage:

BRIEF-Boston Scientific Announces Preliminary Unaudited Sales For Q4 and FY17

* BOSTON SCIENTIFIC ANNOUNCES PRELIMINARY UNAUDITED SALES FOR THE FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2017

Select another date: